Van Tuyl Christopher 4
4 · Immunovant, Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
Immunovant (IMVT) CLO Christopher Van Tuyl Sells Shares
What Happened
Christopher Van Tuyl, Chief Legal Officer of Immunovant, reported sales of 1,206 shares on July 8, 2026, for total proceeds of approximately $47,702. The filing shows two groups: 1,143 shares sold for $45,183 (weighted avg $39.53) and 63 shares sold for $2,519 (weighted avg $39.99). These sales were executed to satisfy tax withholding obligations related to the vesting and settlement of RSUs and were not discretionary trades by the reporting person.
Key Details
- Transaction date: July 8, 2026; Form 4 filed July 10, 2026 (timely filing).
- Shares sold: 1,143 @ weighted avg $39.53 (range $38.91–$39.89) and 63 @ weighted avg $39.99 (range $39.92–$40.03). Total sold = 1,206 shares for ~$47,702.
- Reason: Sell-to-cover to satisfy tax withholding on RSUs granted April 1, 2025; 3,174 RSUs vested July 1, 2026 (footnote F1). The sale was mandated by the issuer’s sell-to-cover election (F1).
- Price details: weighted average prices reported; reporting person will provide per-price breakdown on request (F2, F3).
- Shares owned after transaction: not specified in the summary provided here—see the Form 4 for exact post-transaction holdings.
Context
- This was a tax-withholding sale tied to RSU vesting (routine), not a market-timing or discretionary sale signal. Retail investors often treat mandatory sell-to-cover transactions differently than voluntary insider sales when assessing insider sentiment.
Insider Transaction Report
Form 4
Immunovant, Inc.IMVT
Van Tuyl Christopher
Chief Legal Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-07-08$39.53/sh−1,143$45,183→ 179,454 total - Sale
Common Stock
[F1][F3]2026-07-08$39.99/sh−63$2,519→ 179,391 total
Footnotes (3)
- [F1]On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Signature
/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl|2026-07-10